Attila Louis Major1,2, Vladimír Dvořák3, Jana Schwarzová4, Aleš Skřivánek5, Tomáš Malík6, Marek Pluta7, Ivanna Mayboroda8, Etienne Marc Grandjean9,10. 1. Femina Gynecology Center, Rue Emile-Yung 1, 1205, Geneva, Switzerland. majorattila@outlook.fr. 2. Department of Obstetrics and Gynecology, Cantonal Hospital, University of Fribourg, Fribourg, Switzerland. majorattila@outlook.fr. 3. Centrum ambulantní Gynekologie a primární péče, s.r.o., Brno, Czech Republic. 4. , Smetanova 388, 252 64 Velké Prilepy, Prague-West, Czech Republic. 5. G-CENTRUM Olomouc, s.r.o., Olomouc, Czech Republic. 6. Gyneko spol. s.r.o., Vsetin, Czech Republic. 7. Fakultní Nemocnice v Motole (University Hospital Motol), Onkogynekologická a kolposkopická Ambulance, Praha, Czech Republic. 8. Department of Obstetrics and Gynecology, University Hospital of Geneva, Geneva, Switzerland. 9. Phidalsa Pharma-Consultants, Petit-Lancy/Geneva, Switzerland. 10. Camara-Partners, Consultant, Nyon, Switzerland.
Abstract
PURPOSE: The effect of SAM vaginal gel, a medical device containing adsorptive silicon dioxide and antioxidative sodium selenite and citric acid, on histologically-proven cervical intraepithelial neoplasia type 2 (CIN2) as well as p16 positive CIN1, and on the presence of the onco-marker p16 was investigated. METHODS:216 women aged 25-60 years were randomized to either receive an intravaginal daily dose of SAM gel for three 28-day periods, or be followed-up without intervention. The primary endpoint was efficacy, defined as a combined histological and cytological regression. At baseline and after 3 months participants had: a guided biopsy including p16 immunohistochemical (IHC) staining, only if a lesion was visible at colposcopy; a cervical smear for cytology, high-risk human papillomavirus (hr-HPV) and a p16/Ki-67 test. At 6 months a further cytology and p16/Ki-67 test was performed. RESULTS:Regression of CIN lesions was observed in 78 out of 108 patients (72.2%) in the SAM gel arm and in 27 out of 108 patients (25.0%) in the control arm. Similarly, the change in the p16/Ki-67 cytological test status was significantly in favor of the treatment arm. The prevalence of hr-HPV decreased significantly (p < 0.001) in the treatment arm, from 87.0% to 39.8%, while it slightly increased in the control arm, from 78.7% to 83.3%. At 6 months the cytological regression in the treatment group and the highly significant effect on p16/Ki-67 was still present. CONCLUSION:SAM vaginal gel enhances the regression of cervical lesions and clears hr-HPV and p16/Ki-67 in smears significantly, thus offering an active non-destructive management to prevent cervical cancer. TRIAL REGISTRATION NUMBER: ISRCTN11009040, date of registration: 10/12/2019; https://doi.org/10.1186/ISRCTN11009040 ; retrospectively registered.
RCT Entities:
PURPOSE: The effect of SAM vaginal gel, a medical device containing adsorptive silicon dioxide and antioxidative sodium selenite and citric acid, on histologically-proven cervical intraepithelial neoplasia type 2 (CIN2) as well as p16 positive CIN1, and on the presence of the onco-marker p16 was investigated. METHODS: 216 women aged 25-60 years were randomized to either receive an intravaginal daily dose of SAM gel for three 28-day periods, or be followed-up without intervention. The primary endpoint was efficacy, defined as a combined histological and cytological regression. At baseline and after 3 months participants had: a guided biopsy including p16 immunohistochemical (IHC) staining, only if a lesion was visible at colposcopy; a cervical smear for cytology, high-risk human papillomavirus (hr-HPV) and a p16/Ki-67 test. At 6 months a further cytology and p16/Ki-67 test was performed. RESULTS: Regression of CIN lesions was observed in 78 out of 108 patients (72.2%) in the SAM gel arm and in 27 out of 108 patients (25.0%) in the control arm. Similarly, the change in the p16/Ki-67 cytological test status was significantly in favor of the treatment arm. The prevalence of hr-HPV decreased significantly (p < 0.001) in the treatment arm, from 87.0% to 39.8%, while it slightly increased in the control arm, from 78.7% to 83.3%. At 6 months the cytological regression in the treatment group and the highly significant effect on p16/Ki-67 was still present. CONCLUSION: SAM vaginal gel enhances the regression of cervical lesions and clears hr-HPV and p16/Ki-67 in smears significantly, thus offering an active non-destructive management to prevent cervical cancer. TRIAL REGISTRATION NUMBER: ISRCTN11009040, date of registration: 10/12/2019; https://doi.org/10.1186/ISRCTN11009040 ; retrospectively registered.
Authors: Jeanne M Ferrante; Dionne Y Mayhew; Seth Goldberg; Laurie Woodard; Cynthia Selleck; Richard G Roetzheim Journal: J Am Board Fam Pract Date: 2002 Sep-Oct
Authors: Yan Chen Wongworawat; Maria Filippova; Vonetta M Williams; Valery Filippov; Penelope J Duerksen-Hughes Journal: Am J Cancer Res Date: 2016-03-15 Impact factor: 6.166
Authors: Philip E Castle; Rachael Adcock; Jack Cuzick; Nicolas Wentzensen; Norah E Torrez-Martinez; Salina M Torres; Mark H Stoler; Brigitte M Ronnett; Nancy E Joste; Teresa M Darragh; Patti E Gravitt; Mark Schiffman; William C Hunt; Walter K Kinney; Cosette M Wheeler Journal: Arch Pathol Lab Med Date: 2019-11-13 Impact factor: 5.534